Glial cells in neuropathic pain.

Temugin Berta¹, Arkady Khoutorsky², Jing Xu³, Ru-Rong Ji^3,4

¹Pain Research Center, Department of Anesthesiology, University of Cincinnati Medical Center, Cincinnati, Ohio, United States.

²Department of Anesthesia, Alan Edwards Centre for Research on Pain, Faculty of Dental Medicine and Oral Health Sciences, McGill University, Montreal, Quebec, Canada.

³Center for Translational Pain Medicine, Department of Anesthesiology, Duke University Medical Center, Durham, North Carolina, United States.

⁴Department of Neurobiology, Department of Cell Biology, and Department of Integrative Immunology, Duke Institute for Brain Sciences, Duke University Medical Center, Durham, North Carolina, United States.

PubMed PMC DOI PDF

Abstract

Neuropathic pain is a chronic, debilitating condition that affects ∼7-8% of the global population and remains difficult to treat because of limited therapeutic options. Over the past two decades, mounting preclinical evidence has highlighted the crucial role of glial cells in the development, maintenance, and resolution of neuropathic pain. Conditions such as peripheral nerve injury are associated…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.